Drugs / LM-299
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06650566 | Oct 2024 → Dec 2026 expected | cancer | LaNova Medicines Limited | Recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-20 | Merck Sharp & Dohme LLC | MSD Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody msd.com ↗ |
| 2024-12-20 | Merck Sharp & Dohme LLC | Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody merck.com ↗ |
| 2024-11-14 | Merck Sharp & Dohme LLC | MSD Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. msd.com ↗ |
| 2024-11-14 | Merck Sharp & Dohme LLC | Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. merck.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LM-299 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06650566 ↗ |
| Route | Intravenous | “Intravenous Drip” NCT06650566 ↗ |